The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Abstract
Drug transporters are increasingly recognized to be important to drug disposition and response. P-glycoprotein, the encoded product of the human MDR1 (ABCB1) gene, is of particular clinical relevance in that this transporter has broad substrate specificity, including a variety of structurally divergent drugs in clinical use today. Moreover, expression of this efflux transporter in certain tissue compartments such as the gastrointestinal tract and brain capillary endothelial cells limits oral absorption and central nervous system entry of many drugs. Recently, a number of single-nucleotide polymorphisms (SNPs) in MDR1 have been identified. An increasing number of studies have also implicated certain commonly occurring SNPs in MDR1 in problems including altered drug levels and host susceptibility to diseases such as Parkinson's disease, inflammatory bowel disease, refractory seizures, and CD4 cell recovery during human immunodeficiency virus therapy. However, in many such cases, the reported effects of MDR1 SNPs have been inconsistent and, in some cases, conflicting. In this review SNPs in MDR1 in relation to population frequencies, drug levels, and phenotypes are outlined. In addition, issues relating to MDR1 haplotypes, environmental factors, and study design, as potential confounding factors of the observed MDR1 polymorphism effect in vivo, are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
van Helvoort, A., Smith, A. J., Sprong, H., Fritzsche, I., Schinkel, A. H., Borst, P., & van Meer, G. (1996) · Cell · doi:10.1016/s0092-8674(00)81370-7 · Cited by 855
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Cascorbi, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114164 · Cited by 747
Is the multidrug transporter a flippase?
Higgins, C. F., & Gottesman, M. M. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90419-a · Cited by 722
Human P-glycoprotein transports cyclosporin A and FK506.
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53221-x · Cited by 684
Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.
Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T., & Hori, R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35757-0 · Cited by 673
Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W., & Sisodiya, S. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021986 · Cited by 665
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J.-P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07276-8 · Cited by 658
Self-citationOATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Panwala, C. M., Jones, J. C., & Viney, J. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5733 · Cited by 567
Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., Takahashi, M., Kurata, Y., Kigawa, J., Higuchi, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29643-9 · Cited by 533
Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 494
The physiological function of drug-transporting P-glycoproteins
Schinkel, A. H. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0068 · Cited by 458
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00006 · Cited by 429
Ameyaw, M.-M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., Thornton, N., Folayan, G. O., Githang'a, J., Indalo, A., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00005 · Cited by 409
Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J. J., Wilkinson, G. R., & Kim, R. B. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15144-6 · Cited by 395
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382
Hitzl, M., Drescher, S., van der Kuip, H., Schäffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., & Fromm, M. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00003 · Cited by 374
P-glycoprotein expression and function in circulating blood cells from normal volunteers
Klimecki, W., Futscher, B., Grogan, T., & Dalton, W. (1994) · Blood · doi:10.1182/blood.v83.9.2451.2451 · Cited by 353
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis
Schwab, M., Schaeffeler, E., Marx, C., Fromm, M. F., Kaskas, B., Metzler, J., Stange, E., Herfarth, H., Schoelmerich, J., Gregor, M., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50010 · Cited by 323
Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1012244520615 · Cited by 322
Single-nucleotide polymorphisms can cause different structural folds of mRNA
Shen, L. X., Basilion, J. P., & Stanton, V. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7871 · Cited by 317
Macphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
Lankas, G. R., Wise, L. D., Cartwright, M. E., Pippert, T., & Umbenhauer, D. R. (1998) · Reproductive Toxicology · doi:10.1016/s0890-6238(98)00027-6 · Cited by 314
Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
Johne, A., Köpke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129196 · Cited by 306
Inhibition of P-Glycoprotein by Newer Antidepressants
Weiss, J., Dormann, S.-M. G., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., & Haefeli, W. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046532 · Cited by 292
Tang, K., Ngoi, S.-M., Gwee, P.-C., Chua, J. M. Z., Lee, E. J. D., Chong, S. S., & Lee, C. G. L. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00004 · Cited by 285
Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K. F., van Asperen, J., Borst, P., & Schinkel, A. H. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15775.x · Cited by 282
Frequency of C3435T polymorphism of MDR1 gene in African people
Schaeffeler, E., Eichelbaum, M. F., Brinkmann, U., Penger, A., Asante-Poku, S., Zanger, U. M., & Schwab, M. G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05579-9 · Cited by 281
Anglicheau, D., Verstuyft, C. A. A., Laurent-Puig, P., Becquemont, L., Schlageter, M.-H. A. A. G. A., Cassinat, B., Beaune, P., Legendre, C., & Thervet, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000073901.94759.36 · Cited by 281
Goh, B.-C., Lee, S.-C., Wang, L.-Z., Fan, L., Guo, J.-Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.-L., Ong, A.-B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.025 · Cited by 270
Kurata, Y., Ieiri, I., Kimura, M., Morita, T., Irie, S., Urae, A., Ohdo, S., Ohtani, H., Sawada, Y., Higuchi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126177 · Cited by 269
Schuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
Nakamura, T., Sakaeda, T., Horinouchi, M., Tamura, T., Aoyama, N., Shirakawa, T., Matsuo, M., Kasuga, M., & Okumura, K. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122055 · Cited by 260
MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadine
Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M., & Fromm, M. F. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01591.x · Cited by 249
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.
Illmer, T., Schuler, U. S., Thiede, C., Schwarz, U. I., Kim, R. B., Gotthard, S., Freund, D., Schäkel, U., Ehninger, G., & Schaich, M. A. (2002) · PubMed · Cited by 248
Siegsmund, M., Brinkmann, U., Scha[Combining Acute Accent]ffeler, E., Weirich, G., Schwab, M., Eichelbaum, M., Fritz, P., Burk, O., Decker, J., Alken, P., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000019412.87412.bc · Cited by 246
Uhr, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00095-0 · Cited by 244
Gaikovitch, E. A., Cascorbi, I., Mrozikiewicz, P. M., Brockm�ller, J., Fr�tschl, R., K�pke, K., Gerloff, T., Chernov, J. N., & Roots, I. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0606-2 · Cited by 237
Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects
Ito, S., Ieiri, I., Tanabe, M., Suzuki, A., Higuchi, S., & Otsubo, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200103000-00008 · Cited by 234
Potschka, H., Fedrowitz, M., & Löscher, W. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00423-8 · Cited by 226
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy
Sparreboom, A., Danesi, R., Ando, Y., Chan, J., & Figg, W. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00005-0 · Cited by 226
Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor
Polli, J. W., Jarrett, J. L., Studenberg, S. D., Humphreys, J. E., Dennis, S. W., Brouwer, K. R., & Woolley, J. L. (1999) · Pharmaceutical Research · doi:10.1023/a:1018941328702 · Cited by 218
P-Glycoprotein Deficiency in a Subpopulation of CF-1 Mice Enhances Avermectin-Induced Neurotoxicity
Lankas, G. R., Cartwright, M. E., & Umbenhauer, D. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8086 · Cited by 208
Roberts, R. L., Joyce, P. R., Mulder, R. T., Begg, E. J., & Kennedy, M. A. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500099 · Cited by 202
Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*
Wakasugi, H., Yano, I., Ito, T., Hashida, T., Futami, T., Nohara, R., Sasayama, S., & Inui, K.-I. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90030-3 · Cited by 200
Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K., & Cascorbi, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127739 · Cited by 199
Goto, M., Masuda, S., Saito, H., Uemoto, S., Kiuchi, T., Tanaka, K., & Inui, K.-I. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00005 · Cited by 193
Wu, X., Whitfield, L. R., & Stewart, B. H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007525616017 · Cited by 189
Droździk, M., Białecka, M. A., Myśliwiec, K., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003) · PubMed · doi:10.1097/01.fpc.0000054087.48725.d9 · Cited by 189
Yamauchi, A., Ieiri, I., Kataoka, Y., Tanabe, M., Nishizaki, T., Oishi, R., Higuchi, S., Otsubo, K., & Sugimachi, K. (2002) · Transplantation · doi:10.1097/00007890-200208270-00024 · Cited by 184
Karlsson, J., Kuo, S., Ziemniak, J., & Artursson, P. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13914.x · Cited by 180
Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., & Whitfield, L. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004000112 · Cited by 179
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Kioka, N., Tsubota, J., Kakehi, Y., Komano, T., Gottesman, M. M., Pastan, I., & Ueda, K. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91985-2 · Cited by 175
The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
de Lannoy, I. A. M., & Silverman, M. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91593-f · Cited by 170
Digoxin pharmacokinetics and MDR1 genetic polymorphisms
Verstuyft, C., Schwab, M., Schaeffeler, E., Kerb, R., Brinkmann, U., Jaillon, P., Funck-Brentano, C., & Becquemont, L. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0567-5 · Cited by 166
Mickley, L. A., Lee, J.-S., Weng, Z., Zhan, Z., Alvarez, M., Wilson, W., Bates, S. E., & Fojo, T. (1998) · Blood · doi:10.1182/blood.v91.5.1749 · Cited by 162
P-GLYCOPROTEIN SYSTEM AS A DETERMINANT OF DRUG INTERACTIONS: THE CASE OF DIGOXIN–VERAPAMIL
VERSCHRAAGEN, M., KOKS, C. H. W., SCHELLENS, J. H. M., & BEIJNEN, J. H. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0535 · Cited by 159
Saitoh, H., & Aungst, B. J. (1995) · Pharmaceutical Research · doi:10.1023/a:1016217505990 · Cited by 158
Kimchi‐Sarfaty, C., Gribar, J. J., & Gottesman, M. M. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.1 · Cited by 156
Steroid Transport, Accumulation, and Antagonism of P-Glycoprotein in Multidrug-Resistant Cells
Barnes, K. M., Dickstein, B., Cutler, G. B., Fojo, T., & Bates, S. E. (1996) · Biochemistry · doi:10.1021/bi952380k · Cited by 154
Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I., & Roots, I. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01691.x · Cited by 151
Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells
Callaghan, R., & Riordan, J. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82357-2 · Cited by 143
Collett, A., Higgs, N. B., Sims, E. J., Rowland, M., & Warhurst, G. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37939-x · Cited by 136
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
Kerb, R., Aynacioglu, A. S., Brockmöller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgärtner, C., Ongen, H. Z., et al. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500025 · Cited by 135
Wils, P., Phung-Ba, V., Warnery, A., Lechardeur, D., Raeissi, S. D., Hidalgo, I. J., & Scherman, D. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90580-0 · Cited by 131
Horinouchi, M., Sakaeda, T., Nakamura, T., Morita, Y., Tamura, T., Aoyama, N., Kasuga, M., & Okumura, K. (2002) · Pharmaceutical Research · doi:10.1023/a:1020433422259 · Cited by 128
Longuemaux, S., Deloménie, C., Gallou‐Kabani, C., Méjean, A., Vincent‐Viry, M., Bouvier, R., Droz, D., Krishnamoorthy, R., Galteau, M. M., Junien, C., et al. (1999) · PubMed · Cited by 124
Kafka, A., Sauer, G., Jaeger, C., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.5.1117 · Cited by 121
Increased brain P-glycoprotein in morphine tolerant rats
Aquilante, C. L., Letrent, S. P., Pollack, G. M., & Brouwer, K. L. R. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00599-8 · Cited by 117
Wetterich, U., Spahn-Langguth, H., Mutschler, E., Terhaag, B., Rösch, W. H., & Langguth, P. (1996) · Pharmaceutical Research · doi:10.1023/a:1016029601311 · Cited by 110
Zheng, H., Webber, S., Zeevi, A., Schuetz, E. G., Zhang, J., Lamba, J. K., Bowman, P., & Burckart, G. J. (2002) · Human Immunology · doi:10.1016/s0198-8859(02)00426-3 · Cited by 108
P-Glycoprotein-Mediated Transport of Itraconazole across the Blood-Brain Barrier
Miyama, T., Takanaga, H., Matsuo, H., Yamano, K., Yamamoto, K., Iga, T., Naito, M., Tsuruo, T., Ishizuka, H., Kawahara, Y., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1738 · Cited by 108
Altered Expression of Hepatic Cytochromes P-450 in Mice Deficient in One or More mdr1 Genes
Schuetz, E. G., Umbenhauer, D. R., Yasuda, K., Brimer, C., Lan, N. T. N., Relling, M. V., Schuetz, J. D., & Schinkel, A. H. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26457-9 · Cited by 106
Allosteric Modulation of Human P-glycoprotein
Maki, N., Hafkemeyer, P., & Dey, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210413200 · Cited by 94
Nasi, M., Borghi, V., Pinti, M., Bellodi, C., Lugli, E., Maffei, S., Troiano, L., Richeldi, L., Mussini, C., Esposito, R., et al. (2003) · AIDS · doi:10.1097/00002030-200307250-00016 · Cited by 94
Schuetz, E. G., Yasuda, K., Arimori, K., & Schuetz, J. D. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0537 · Cited by 91
P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agents
SAEKI, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81540-g · Cited by 91
Lee, C. G. L., Ramachandra, M., Jeang, K., Martin, M. A., Pastan, I. H., & Gottesman, M. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.3.516 · Cited by 90
Pariante, C. M., Kim, R. B., Makoff, A., & Kerwin, R. W. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705357 · Cited by 89
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture
Perloff, M. D., Moltke, L. L., Fahey, J. M., et al. (2000) · AIDS · doi:10.1097/00002030-200006160-00034 · Cited by 83
Tamai, I., Yamashita, J., Kido, Y., Ohnari, A., Sai, Y., Shima, Y., Naruhashi, K., Koizumi, S., & Tsuji, A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38880-9 · Cited by 83
Lin, J. H., Chiba, M., Chen, I., et al. (1999) · PubMed · Cited by 83
Smit, J. W., Schinkel, A. H., Müller, M. M., Weert, B., & Meijer, D. K. F. (1998) · Hepatology · doi:10.1002/hep.510270422 · Cited by 78
Frittitta, L., Ercolino, T., Bozzali, M., Argiolas, A., Graci, S., Santagati, M. G., Spampinato, D., Paola, R. D., Cisternino, C., Tassi, V., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1952 · Cited by 77
The mechanism of ATP-dependent multidrug transport by P-glycoprotein.
Shapiro, A. B., & Ling, V. W. T. (1998) · PubMed · Cited by 76
Pham, Y.-T., Régina, A., Farinotti, R., Couraud, P., Wainer, I. W., Roux, F. S., & Gimenez, F. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(00)00160-4 · Cited by 75
Saitoh, H., Hatakeyama, M., Eguchi, O., Oda, M., & Takada, M. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970163u · Cited by 63
Relling, M. V. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199608000-00006 · Cited by 60
Arimori, K., Kuroki, N., Hidaka, M., Iwakiri, T., Yamasaki, K., Okumura, M., Ono, H., Takamura, N., Kikuchi, M., & Nakano, M. (2003) · Pharmaceutical Research · doi:10.1023/a:1023847521767 · Cited by 59
Calado, R. T., Falcão, R. P., Garcia, A. B., Gabellini, S. M., Zago, M. A., & Franco, R. F. (2002) · PubMed · Cited by 59
Takara, K., Tanigawara, Y., Komada, F., Nishiguchi, K., Sakaeda, T., & Okumura, K. (1999) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.22.1355 · Cited by 58
Speck, R., Yu, X., Hildreth, J. E. K., & Flexner, C. W. (2002) · The Journal of Infectious Diseases · doi:10.1086/341464 · Cited by 57
Hafny‐Rahbi, B. E., Chappey, O., Piciotti, M., Debray, M., Boval, B., & Roux, F. S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00679-4 · Cited by 55
Oselin, K., Gashaw, I., Mrozikiewicz, P. M., et al. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01133.x · Cited by 53
Paine, M. F., Leung, L. Y., Lim, H., Liao, K., Oganesian, A., Zhang, M.-Y., Thummel, K. E., & Watkins, P. B. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.174 · Cited by 49
Wang, E., Lew, K., Barecki-Roach, M., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010125x · Cited by 47
Kavallaris, M., Madafiglio, J., Norris, M. D., & Haber, M. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1013 · Cited by 39
Woodland, C., Verjee, Z. H., Giesbrecht, E. E., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37024-7 · Cited by 38
Pippert, T. R., & Umbenhauer, D. R. (2001) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.3 · Cited by 32
Pedersen, K. E. (1985) · PubMed · Cited by 29
Tateishi, T., Nakura, H., Asoh, M., Watanabe, M., Tanaka, M., Kumai, T., & Kobayashi, S. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00374-7 · Cited by 24
Cited by
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Metadata
- Authors
- Marzolini, C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-01
- Volume
- 75
- Issue
- 1
- Pages
- 13-33
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2163636362
- Cited by
- 895
- References
- 116
- FWCI
- 65.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.